What does Adaptimmune Therapeutics do?
Adaptimmune Therapeutics (NASDAQ:ADAP) focuses on the development of novel cancer immunotherapy products. Its main efforts are in spearheading the engineering of specific T-cell receptors (TCRs) for the treatment of cancer. Adaptimmune seeks to harness the power of the body's own immune system to target and destroy cancer cells by enhancing the natural ability of T-cells to fight the disease. With a pipeline of projects in various stages of development, the company aims to deliver innovative therapies for people with cancer, advancing treatments beyond current options. Their objective is to provide new, life-changing options for patients battling cancer, targeting a range of solid tumors and hematologic cancers.